Ipsen sells the North American development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria